Orthocell reports record $13.2 million annual revenue, driven by 36% quarterly growth in Remplir™ product sales.
Orthocell Ltd (ASX:OCC) posted record revenue of $3.8 million for the June quarter, a 20% increase from the prior quarter and 36% higher year-over-year. The result lifted full-year FY2026 revenue to $13.2 million, up 44% from the previous financial year.
Growth was fueled by expanding global sales of its Remplir™ nerve repair and Striate+™ products, with the June quarter marking the company’s strongest performance to date. The company noted a 10% compound quarterly growth rate over the past 10 quarters.
The S&P/ASX Small Ordinaries Index closed Friday at 3,392.70, up 0.70% for the session but down 1.42% over the past five trading days.